Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...

WW International, known as WeightWatchers, saw its stock soar on new of its new compounded GLP-1 offering. But analysts say ...

Concerns are rising as Novo Nordisk's $16.5 billion bid to acquire Catalent faces scrutiny from the FTC. Critics argue the ...

Data readouts over the next six months could set expectations for how the highly lucrative market for weight loss therapies ...

The letter indicates that Novo Nordisk already has 55% of the market for diabetes and obesity through its blockbuster Ozempic ...

U.S. Senator Elizabeth Warren has asked antitrust regulators to scrutinize a $16.5 billion deal in which Novo Nordisk's ...

As Novo Holdings hopes to close its $16.5 billion acquisition of CDMO Catalent by the end of the year, the deal is facing a fresh round of lawmaker scrutiny. | In a letter to the chair of the U.S.

Eli Lilly and Novo Nordisk are already the biggest drug companies by market capitalisation that have ever drug companied, and there is reason to think they may be getting even bigger. And the reason, ...

WW International, known as WeightWatchers, saw its stock soar on new of its new compounded GLP-1 offering. But analysts say that's only a short-term solution to its ailing business.

Sen. Elizabeth Warren (D-MA) is calling on the Federal Trade Commission to carefully evaluate Novo Nordisk Foundation's ...

The surge in popularity of drugs like Ozempic, driven in part by its weight loss benefits, is contributing to a record-high ...